8月7日，诺和诺德盘中上涨3.15%，报46.92美元/股，成交额8089.98万美元。
消息面上，公司此前发布Q2财报，调整后EPS为0.96美元，超市场预期0.81美元达18.5%；销售额122.09亿美元，超预期113.5亿美元，公司同步上调全年销售及营业利润指引，主要由GLP-1产品销售预期提升推动。此外，荷兰海牙地区法院裁定Ceban公司复方司美格鲁肽鼻喷雾剂侵犯诺和诺德专利权并下达临时禁令，进一步巩固其GLP-1核心资产知识产权壁垒。BMO亦将公司目标价从45美元上调至47美元。此前公司因心脏新药ziltivekimab三期试验失败股价曾暴跌近10%，当前连续反弹反映市场对核心GLP-1业务韧性及专利保护力度的重新定价。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.